Nebula Genomics Signs Agreement for Pilot Project with EMD Serono

Nebula Genomics, which operates a technology platform containing genome-sequencing data, has signed an agreement with EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, for EMD Serono to access genomic data on Nebula's blockchain-based network for genomic data sharing.

Nebula aims to help EMD Serono enhance its research efforts by supporting its scientists as they develop potential new medicines, using Nebula's network of anonymized genomic data.

"This collaboration pioneers a new business model in personal genomics that benefits both individuals and researchers such as those at EMD Serono," said Dennis Grishin, Chief Scientific Officer of Nebula Genomics. "We want to help patients benefit from their data and also empower them to actively contribute to research. Our goal is to spearhead a more patient-centric approach to medical research where pharmaceutical companies and patients are working together to accelerate drug development."

Genomics has the potential to transform healthcare and biomedical research. As researchers are hindered by the overall lack of data as well as difficult data access due to data fragmentation and inefficient consent management, Nebula's platform offers a solution to tackle these challenges. It connects patients and consumers with researchers and incentivizes data sharing by ensuring equitable compensation, transparency and security.